Argus Raises Corteva (NYSE:CTVA) Price Target to $91.00

Corteva (NYSE:CTVA) had its price target lifted by equities researchers at Argus from $80.00 to $91.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Argus’ price objective would suggest a potential upside of 9.02% from the stock’s previous close.

A number of other equities analysts also recently weighed in on CTVA. Mizuho upped their target price on Corteva from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, February 17th. JPMorgan Chase & Co. downgraded shares of Corteva from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $75.00 to $77.00 in a research report on Thursday, February 5th. Royal Bank Of Canada increased their target price on shares of Corteva from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Oppenheimer set a $86.00 target price on shares of Corteva in a research note on Thursday, February 5th. Finally, CICC Research boosted their price target on shares of Corteva from $70.00 to $80.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Fourteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.45.

Corteva Stock Up 0.6%

Shares of Corteva stock traded up $0.52 during midday trading on Tuesday, hitting $83.47. The company’s stock had a trading volume of 815,384 shares, compared to its average volume of 4,138,459. Corteva has a 1-year low of $53.40 and a 1-year high of $83.97. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $56.04 billion, a P/E ratio of 52.85, a PEG ratio of 2.80 and a beta of 0.72. The stock has a 50-day simple moving average of $76.52 and a 200-day simple moving average of $69.72.

Corteva (NYSE:CTVA) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same period in the previous year, the firm earned $0.32 earnings per share. Corteva’s quarterly revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts expect that Corteva will post 2.96 earnings per share for the current year.

Insider Buying and Selling at Corteva

In related news, insider Brian Titus sold 8,311 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.15% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Activest Wealth Management grew its stake in shares of Corteva by 118.3% in the third quarter. Activest Wealth Management now owns 369 shares of the company’s stock worth $25,000 after acquiring an additional 200 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in Corteva in the 3rd quarter worth $25,000. True Wealth Design LLC increased its holdings in shares of Corteva by 209.5% during the 3rd quarter. True Wealth Design LLC now owns 390 shares of the company’s stock worth $26,000 after purchasing an additional 264 shares during the period. Total Investment Management Inc. acquired a new position in shares of Corteva during the second quarter valued at about $27,000. Finally, Garton & Associates Financial Advisors LLC bought a new stake in shares of Corteva in the fourth quarter valued at about $27,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.